Fig. 5From: THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumoursCombination treatment with THZ1 and imatinib for GIST. A CCK-8 viability assay following treatment for 72Â h with escalating concentrations of THZ1 and imatinib in GIST-T1 and GIST-882 cells. BÂ GIST-T1 cells received single 20Â nmol/L imatinib, THZ1 and a combination treatment for 72Â h. GIST-882 cells received single 50Â nmol/L imatinib, THZ1 and a combination treatment for 72Â h. The cell viability of combination treatment group was significantly suppressed than monotherapy. C Synergy was calculated using CompuSyn, and a combination index value under 1.0 was considered to indicate synergy. D Immunoblotting analysis of cleaved caspase 3 and cleaved PARP protein expression after combination treatment with THZ1 and imatinib in GIST-T1 and GIST-882 cells for 24Â hBack to article page